Trial · NCT00183170

Residual Effects of Intoxication on Student Performance

NCT00183170, Phase 2, Completed, Boston University; results first posted 2020-12-04

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Residual Effects of Intoxication on Student Performance. Trials, record NCT00183170. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00183170

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Residual Effects of Intoxication on Student Performance
NCT number: NCT00183170
Status: Completed
Phases: Phase 2
Enrollment: 239 participants, actual
Lead sponsor: Boston University
Conditions: Alcoholic Intoxication, Neurobehavioral Manifestations
Interventions: Alcohol, Placebo
First posted: 2005-09-16
Last updated: 2020-12-08
Results first posted: 2020-12-04

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Self-reported Residual Effects of Heavy Drinking	next day	This outcome will be measured by the afternoon total mood disturbance score. This is part of the Profile of Mood States Questionnaire (POMS). POMS is a 35 item instrument with Likert responses from 0 to 4 where 0=not at all and 4=extremely. Range of scores can be 0 to 140, lower scores are more favorable.
Secondary	Cognitive Function in Response to Heavy Drinking	next day	This outcome measure will be assessed using the Visual Span Test- Backwards (VST-B). This is the mean maximum span of words repeated backwards correctly. Higher scores are more favorable
Secondary	Academic Function in Response to Heavy Drinking	next day	This outcome will be measured by the mean Graduate Record Exam (GRE) quantitative score. The quantitative score can range from 200-800. Higher scores are more favorable.
Secondary	Reaction Time Affected by Residual Effects of Heavy Drinking	next day	This outcome will be measured with the Continuous Performance Test (CPT) for reaction time in mean milliseconds (ms). Lower reaction times are more favorable.
Secondary	Effectiveness of Psychomotor Vigilance Testing as a Fitness-for-duty Test	next day	This outcome will be assessed with the Psychomotor Vigilance Test (PVT) in median milliseconds. The 10-min PVT measures sustained or vigilant attention by recording response times to visual (or auditory) stimuli that occur at random inter-stimulus intervals. Lower number of milliseconds are associated with greater vigilant attention.

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Self-reported Residual Effects of Heavy Drinking	next day	153 POMS questionnaires were analyzed since 40 of the 193 participants did not return the POMS questionnaire by the next day.	scores on a scale	MEAN
SECONDARY	Cognitive Function in Response to Heavy Drinking	next day	Data were analyzed for 186 of the 193 participants since 7 did not complete the VST-B.	backwards words	MEAN
SECONDARY	Academic Function in Response to Heavy Drinking	next day		score on a scale	MEAN
SECONDARY	Reaction Time Affected by Residual Effects of Heavy Drinking	next day	Data were analyzed for 187 of the 193 participants since 6 did not complete the CPT.	milliseconds	MEAN
SECONDARY	Effectiveness of Psychomotor Vigilance Testing as a Fitness-for-duty Test	next day	Data were analyzed for 190 of the 193 participants since 3 did not complete the PVT.	milliseconds of response time	MEDIAN

Source ClinicalTrials.gov

Results by group10

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Self-reported Residual Effects of Heavy Drinking	Alcohol	4.3	Standard Deviation 10.19	scores on a scale
Self-reported Residual Effects of Heavy Drinking	Placebo	1.93	Standard Deviation 8.39	scores on a scale
Cognitive Function in Response to Heavy Drinking	Alcohol	5.41	Standard Deviation 0.89	backwards words
Cognitive Function in Response to Heavy Drinking	Placebo	5.67	Standard Deviation 1.16	backwards words
Academic Function in Response to Heavy Drinking	Alcohol	615.75	Standard Deviation 98.92	score on a scale
Academic Function in Response to Heavy Drinking	Placebo	612.38	Standard Deviation 94.64	score on a scale
Reaction Time Affected by Residual Effects of Heavy Drinking	Alcohol	378.77	Standard Deviation 35.48	milliseconds
Reaction Time Affected by Residual Effects of Heavy Drinking	Placebo	375.98	Standard Deviation 35.82	milliseconds
Effectiveness of Psychomotor Vigilance Testing as a Fitness-for-duty Test	Alcohol	223.40	Standard Deviation 22.81	milliseconds of response time
Effectiveness of Psychomotor Vigilance Testing as a Fitness-for-duty Test	Placebo	218.57	Standard Deviation 20.25	milliseconds of response time

Source ClinicalTrials.gov

Participant flow18

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
First Intervention	STARTED	Alcohol, Then Placebo	103
First Intervention	STARTED	Placebo, Then Alcohol	109
First Intervention	COMPLETED	Alcohol, Then Placebo	101
First Intervention	COMPLETED	Placebo, Then Alcohol	109
First Intervention	NOT COMPLETED	Alcohol, Then Placebo	2
First Intervention	NOT COMPLETED	Placebo, Then Alcohol	0
Washout 1 Week	STARTED	Alcohol, Then Placebo	101
Washout 1 Week	STARTED	Placebo, Then Alcohol	109
Washout 1 Week	COMPLETED	Alcohol, Then Placebo	95
Washout 1 Week	COMPLETED	Placebo, Then Alcohol	101

1 to 10 of 18Source ClinicalTrials.gov

See all 18 participant flow

Adverse events2

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Vomiting	Gastrointestinal disorders	Alcohol	5	193	5
other	Vomiting	Gastrointestinal disorders	Placebo	0	193	0

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Alcohol
Total, all-cause mortality	Placebo
Total, other adverse events	Alcohol	5	193
Total, other adverse events	Placebo	0	193
Total, serious adverse events	Alcohol	0	193
Total, serious adverse events	Placebo	0	193

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
21859168	DERIVED

Source PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
P60AA013759	Center to Prevent Alcohol Problems Among Young People	ROSENBLOOM, DAVID L	BOSTON UNIVERSITY MEDICAL CAMPUS	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM	2004 to 2009

Source NIH RePORTER

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Alcohol vs Placebo: serious adverse events

Source Trial comparisons

Tests2

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

Test	Named as	Source
Continuous Performance Test	Secondary outcome	ConductCognition
Psychomotor Vigilance Task	Secondary outcome	ConductCognition

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00183170

GET https://conductscience.org/api/trials/v1/NCT00183170/registered

API reference For AI assistants